The Dutch health-technology company backed its full-year guidance. It expects to deliver low-to-mid-single-digits comparable sales growth for 2021.
The Dutch health-technology company backed its full-year guidance. It expects to deliver low-to-mid-single-digits comparable sales growth for 2021.
lecrab 
lecrab